U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07705438) titled 'Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC' on Sept. 13, 2025.
Brief Summary: This study plans to enroll 30 patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are scheduled to receive at least two cycles of a regimen containing an immune checkpoint inhibitor (ICI). All ICI treatments must be administered in accordance with current clinical indications. For patients who intend to participate in a clinical trial involving an ICI, they must meet the eligibility criteria of that specific trial protocol.
After screening and enrollment, participants will undergo a [68Ga]Ga-DOTA-GSI PET/CT...